No public input from biopharma on emerging tech for export controls

As the comment period for input on how to define emerging technologies under the Export Control Reform Act of 2018 draws to a close Thursday, a lack of publicly available comments from biopharma companies precludes insight into the industry's strategy for protecting its ability to out-license technology to foreign entities.

The U.S. Department of Commerce received authority to create export controls for "emerging and foundational technologies" under the law. As the department considers updates to its export controls list, its Bureau of Industry and Security (BIS) sought public input on the definition of emerging technology through an advance notice of proposed rulemaking (ANPRM) (see "Clock Ticking for Input on Emerging Biotech for Export Controls")...